Diagnostics and Therapeutics for Lung Cancer: Global Markets

NEW YORK, June 8, 2015 /PRNewswire/ -- This BCC Research report analyzes the market for diagnostics and therapeutics for lung cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics.

Use this report to:
- Analyze market revenues of the global lung cancer market segments and subsegments based on geographies and products.
- Identify regulations and government supported programs impacting the lung cancer market.
- Learn about various lung cancer diagnostics tests and lung cancer therapeutics like chemotherapy, radiotherapy and surgery.

Highlights
- The global market for lung cancer grew to $21.9 billion in 2014 from $20.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 7.8% from 2014 to 2019, totaling $31.8 billion in 2019.
- The Asia-Pacific market totaled nearly $7 billion in 2013. This market is estimated to grow from $7.5 billion in 2014 to nearly $11.3 billion by 2019 at a CAGR of 8.5%.
- The European market for lung cancer totaled $6.1 billion in 2013. This market is expected to grow from $6.6 billion in 2014 to $9.5 billion by 2019 at a CAGR of 7.6%.

Introduction & Scope

INTRODUCTION
This report discusses the global lung cancer market in terms of growth, size and opportunities. The report analyzes the market for diagnostics and therapeutics for lung
cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics. Regionally, the study focuses on North America,
Europe, Asia-Pacific and Rest of the World.

STUDY AND OBJECTIVES
- Define and discuss the global lung cancer market.
- Analyze market structure by segments and subsegments.
- Estimate market revenues of the global lung cancer market segments and subsegments by geographies and products.
- Identify market trends, issues and factors impacting lung cancer market.
- Explain opportunities in the lung cancer market with respect to geography, diagnostics and therapeutics.
- Profile major players and analyze their core competencies and strategies for the lung cancer market.
- Track alliances, joint ventures, mergers and acquisitions, new product developments, and research and development in the global lung cancer market.

TITLE DESCRIPTION
Lung cancer is the number one cancer that has fatally affected the most people in the U.S., and is more prevalent than breast, prostate and colon cancers. The survival rate
of lung cancer is extremely low; an efficient, early-stage diagnostic test has still not been identified. Tobacco smoke is the prime reason for developing lung cancer. There
are two types of lung cancer: small cell lung cancer (SCLC), which is around 15%; and non-small cell lung cancer (NSCLC), which is 85% of the total lung cancers. SCLC
cannot be operated upon, and hence the survival rate is low. NSCLC is the more common of the two types of lung cancer, and its growth is slower compared to the
SCLC. It is of three types as per the cell structure: squamous cell carcinoma, adenocarcinoma and the large cell carcinoma.

SCOPE OF THE REPORT
The report will analyze the lung cancer market as per diagnostics and therapeutics, and will also focus on the regulations and government supported programs impacting
this market. Regionally, the focus of study will be the markets of North America, Europe, Asia-Pacific and Rest of the World (ROW). This report includes various lung cancer diagnostics tests like histology/cytology, immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, and molecular biomarkers, etc. Lung cancer therapeutics include chemotherapy, radiotherapy and surgery.

MARKET STRUCTURE
The global lung cancer markets analyzed in the report include the competitive landscape and profiles of key players of the lung cancer market as well as regional and
product analysis. The global lung cancer market is also broken down by the diagnostics and therapeutics market.

INTENDED AUDIENCE
- Equipment distributors, hospitals and other healthcare service providers.
- Life sciences companies and diagnostic laboratories.
- Research institutes, associations and academicians.

RESEARCH METHODOLOGY
A top-down approach was taken to estimate the size of the lung cancer market. To calculate market sizes, the following details were taken into account:
- Revenues of the lung cancer market are determined through primary and secondary research, including a study of the annual reports of listed market players.
- Secondary research includes a general search by keywords through paid sources such as Factiva as well as other publicly available websites and company websites.
- Micro markets are estimated through primary and secondary sources, and validated through primary sources.
- Forecasts are based on the analysis of market trends, market dynamics and strategies of key companies.
- Geographic estimates are derived from secondary sources verified through primary sources.
Read the full report: http://www.reportlinker.com/p03007880-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com